Tarpeyo (Budesonide) Is Transforming IgA Nephropathy Care with FDA’s Full Approval
XTalks
JANUARY 8, 2024
Initially receiving accelerated approval in December 2021 based on proteinuria as a surrogate marker, Tarpeyo has now achieved the status of being the first treatment for IgAN to receive full FDA approval predicated on evaluations of kidney function.
Let's personalize your content